What is the difference between reclast and zometa

Within the osteoclast it inhibits the action of the enzyme farnesyl pyrophosphate synthase, resulting in disruption of the osteoclast cytoskeleton and cell death. This action prevents the increased osteoclastic activity and accompanying skeletal calcium release of certain tumors and other conditions. Aromatase inhibitor-associated bone loss AIBL. Bone metastases from solid tumors in conjunction with standard antineoplastic therapy.

Prevention of bone loss associated with aromatase inhibitor therapy for breast cancer in postmenopausal women or premenopausal women on adjuvant ovarian suppression. Prevention of bone loss associated with androgen deprivation therapy in men with prostate cancer. Note: patients discontinuing treatment with denosumab due to a reduction in fracture risk i.

One administration is allowed for this use prior to temporary discontinuation of intravenous antiresorptive therapy. Prevention or treatment of osteoporosis in men with prostate cancer during androgen deprivation therapy. Langerhans Cell Histiocytosis:. Prevention of aromatase inhibitor-induced bone loss in breast cancer. Prevention of androgen deprivation-induced bone loss in prostate cancer. Langerhans Cell Histiocytosis. Prevention of osteoporosis in post-menopausal women.

Prevention of glucocorticoid-induced osteoporosis. Prevention of bone loss in breast cancer. Prevention of osteoporosis in postmenopausal women. We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it.

The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service or supply that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed.

If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia e. Zometa [package insert]. Stein, Switzerland; Novartis Pharmaceuticals; December Accessed February Results: The study cohort consisted of patients 51 denosumab, 56 ZA. The denosumab group had a greater mean increase in spine BMD at 1 year 0.

The change in femur and spine BMD at 1 year were not significantly different between the 2 groups. Conclusion: The denosumab group had a higher mean increase in spine BMD, and the ZA group had a higher incidence of flu-like symptoms, but the study groups were statistically similar in terms of patient satisfaction. Reclast zoledronic acid and Prolia denosumab are two injectable drugs that treat osteoporosis.

While both medications can treat postmenopausal osteoporosis, Reclast is also approved to prevent postmenopausal osteoporosis.

Both Reclast and Prolia can also decrease the risk of fracture for some men and women with certain conditions. Reclast is administered once a year or once every 2 years while Prolia is administered every 6 months.

Prolia also needs to be taken with supplemental calcium and vitamin D to prevent hypocalcemia. However, both Reclast and Prolia are not recommended in cases of already established hypocalcemia. In one comparative study of zoledronic acid and denosumab, denosumab showed a greater increase in spinal bone mass density BMD compared to zoledronic acid. Zoledronic acid also showed a greater incidence of flu-like symptoms. Based on this study, Prolia may be more effective for certain people.

While both medications are effective, one may be more suitable depending on other factors such as medical history and other medications being taken. Skip to main content Search for a topic or drug. Reclast vs Prolia: Main Differences and Similarities. By Gerardo Sison, Pharm. Top Reads in Drug vs.

Toujeo vs Lantus: Main Differences and S